Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer
Status:
Not yet recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-center, multi-corhort Phase II study of Envafolimab alone or
with Lenvatinib in patients with advanced endometrial cancer.The primary objective is to
evaluate objective response rate of envafolimab alone or with lenvatinib.